146 related articles for article (PubMed ID: 23819695)
1. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
Yap C; Pettitt A; Billingham L
BMC Med Res Methodol; 2013 Jul; 13():87. PubMed ID: 23819695
[TBL] [Abstract][Full Text] [Related]
2. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints.
Wu J; Pan H; Hsu CW
Biom J; 2022 Oct; 64(7):1207-1218. PubMed ID: 35661226
[TBL] [Abstract][Full Text] [Related]
3. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
[TBL] [Abstract][Full Text] [Related]
4. Early selection in a randomized phase II clinical trial.
Steinberg SM; Venzon DJ
Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
[TBL] [Abstract][Full Text] [Related]
5. Between-arm comparisons in randomized Phase II trials.
Jung SH; George SL
J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
[TBL] [Abstract][Full Text] [Related]
6. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
7. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian pick-the-winner design in a randomized phase II clinical trial.
Chen DT; Huang PY; Lin HY; Chiappori AA; Gabrilovich DI; Haura EB; Antonia SJ; Gray JE
Oncotarget; 2017 Oct; 8(51):88376-88385. PubMed ID: 29179442
[TBL] [Abstract][Full Text] [Related]
9. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
11. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
Wathen JK; Thall PF
Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
13. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
14. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trials: a long-term investment with promising returns.
Sharma MR; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
18. Bayesian two-stage design for phase II oncology trials with binary endpoint.
Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
[TBL] [Abstract][Full Text] [Related]
19. Design issues of randomized phase II trials and a proposal for phase II screening trials.
Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
[TBL] [Abstract][Full Text] [Related]
20. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
